RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Reimbursement in China

Reimbursement in China

Posted 01 October 2010 | By

The global recession has left medical companies scrambling to find new markets. China's gross domestic product, adjusted for purchasing power parity, is currently second in the world and has surpassed Japan's. Medical companies should focus on this growing market. However, before entering the Chinese market, it is essential to investigate the market potential and determine reimbursement for your specific medical product. This article will cover the basics of healthcare in China and how to determine reimbursement for drugs, medical devices and in vitro diagnostics in that marketplace.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.